Adipokines in the treatment of diabetes mellitus and obesity

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 2, 2009, Pages 239-254

  Catalán, Victoria ^a,b   Gómez Ambrosi, Javier ^a   Rodríguez, Amaia ^a   Salvador, Javier ^a,b   Frühbeck, Gema ^a,b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

Adipokines; Insulin resistance; Obesity; Type 2 diabetes mellitus; Visceral adipose tissue

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; CHEMOATTRACTANT; CHEMOATTRACTANT PROTEIN CHEMERIN; ETANERCEPT; EXENDIN 4; GLITAZONE DERIVATIVE; INFLIXIMAB; INSULIN; LACTOFERRIN; LEPTIN; MEMBRANE PROTEIN; METFORMIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OMENTIN; OSTEOPONTIN; PIOGLITAZONE; RECOMBINANT CYTOKINE; RECOMBINANT VASPIN; RECPMBINANT ADIPONECTIN; RETINOL BINDING PROTEIN 4; SIX TRANSMEMBRANE PROTEIN OF PROSTATE 2; SULFONYLUREA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASPIN;

ADD ON THERAPY; ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; BARIATRIC SURGERY; BLOOD GLUCOSE MONITORING; BODY MASS; BONE MASS; CLINICAL TRIAL; COMORBIDITY; CROHN DISEASE; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; EDEMA; ENDOCRINE GLAND; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; FRACTURE; GASTRIC BANDING; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEALTH EDUCATION; HEART FAILURE; HUMAN; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; LIPID STORAGE; LIPOLYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; REVIEW; SELF CARE; SIDE EFFECT; SIGNAL TRANSDUCTION; SUBCUTANEOUS FAT; TREATMENT INDICATION; TREATMENT WITHDRAWAL; WEIGHT GAIN; PHYSIOLOGY;

ADIPOKINES; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; OBESITY; SUBCUTANEOUS FAT;

EID: 65649115846     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560802618811     Document Type: Review

References (188)

1. Sethi JK, Vidal-Puig AJ. Targeting fat to prevent diabetes. Cell Metab 2007;5:323-325 (Pubitemid 46667762)
2. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-1555
3. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-591 (Pubitemid 39025053)
4. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881-887 (Pubitemid 46024995)
5. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006;444:840-846 (Pubitemid 46024990)
6. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875-880 (Pubitemid 46028447)
7. Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 2000;106:165-169 (Pubitemid 30483117)
8. Saltiel AR. The molecular and physiological basis of insulin resistance: emerging implications for metabolic and cardiovascular diseases. J Clin Invest 2000;106:163-164 (Pubitemid 30483116)
9. Muoio DM, Newgard CB. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 2008;9:193-205 (Pubitemid 351301824)
10. Bergman RN, Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 2000;11:351-356 (Pubitemid 30778470)
11. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000;106:473-481 (Pubitemid 30666380)
12. Frühbeck G, Gómez-Ambrosi J. Control of body weight: a physiologic and transgenic perspective. Diabetologia 2003;46:143-172 (Pubitemid 36343879)
13. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001;414:799-806 (Pubitemid 34000783)
14. Muoio DM, Newgard CB. Fatty acid oxidation and insulin action: when less is more. Diabetes 2008;57:1455-1456
15. Boden G. Interaction between free fatty acids and glucose metabolism. Curr Opin Clin Nutr Metab Care 2002;5:545-549 (Pubitemid 40684651)
16. Delarue J, Magnan C. Free fatty acids and insulin resistance. Curr Opin Clin Nutr Metab Care 2007;10:142-148 (Pubitemid 46220305)
17. Arner P. Insulin resistance in type 2 diabetes- role of the adipokines. Curr Mol Med 2005;5:333-339 (Pubitemid 40663138)
18. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111-1119 (Pubitemid 40629025)
19. de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett 2008;582:97-105 (Pubitemid 50010731)
20. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008;454:428-435
21. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008;454:470-477
22. Home P, Mant J, Diaz J, Turner C. Management of type 2 diabetes: summary of updated NICE guidance. BMJ 2008;336:1306-1308 (Pubitemid 351839637)
23. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-1972 (Pubitemid 44156663)
24. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008;31:173-175
25. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365:1333-1346 (Pubitemid 40501297)
26. Hays NP, Galassetti PR, Coker RH. Prevention and treatment of type 2 diabetes: Current role of lifestyle, natural product, and pharmacological interventions. Pharmacol Ther 2008;118:181-191
27. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443 (Pubitemid 44903747)
28. Stafylas PC, Sarafidis PA, Lasaridis AN. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. Int J Cardiol 2008;4:4
29. Delea TE, Edelsberg JS, Hagiwara M, et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003;26:2983-2989 (Pubitemid 37339487)
30. Drazen JM, Morrissey S, Curfman GD. Rosiglitazone - continued uncertainty about safety. N Engl J Med 2007;357:63-64 (Pubitemid 47026737)
31. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471 (Pubitemid 46919772)
32. Buckingham RE, Hanna A. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs? Diabetes Obes Metab 2008;10:312-328
33. Grey A. Thiazolidinedione-induced skeletal fragility- mechanisms and implications. Diabetes Obes Metab 2008;In press. Doi:10.1111/j.1463-1326.2008. 00931.x
34. Rohatgi A, McGuire DK. Effects of the thiazolidinedione medications on micro- and macrovascular complications in patients with diabetes-update 2008. Cardiovasc Drugs Ther 2008;22:233-240
35. Guerci B, Salaun Martin C. Exenatide: Its position in the treatment of type 2 diabetes. Ann Endocrinol 2008;69:201-209
36. Madsbad S, Krarup T, Deacon CF, Holst JJ. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care 2008;11:491-499
37. Salehi M, Aulinger BA, D'Alessio DA. Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr Rev 2008;29:367-379 • A thorough and detailed review about the effects, mechanisms and limitations of incretins. (Pubitemid 351679705)
38. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724-1737 (Pubitemid 39346675)
39. Sjöstrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683-2693 (Pubitemid 39665322)
40. Bikman BT, Zheng D, Pories WJ, et al. Mechanism for improved insulin sensitivity after gastric bypass surgery. J Clin Endocrinol Metab 2008; In press. Doi:10.1210/jc.2008-1030
41. Troy S, Soty M, Ribeiro L, et al. Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice. Cell Metab 2008;8:201-211
42. Frühbeck G, Diez Caballero A, Gil MJ. Fundus functionality and ghrelin concentrations after bariatric surgery. N Engl J Med 2004;350:308-309 (Pubitemid 38067650)
43. Frühbeck G, Diez-Caballero A, Gil MJ, et al. The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus. Obes Surg 2004;14:606-612 (Pubitemid 38716579)
44. le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007;246:780-785
45. Reinehr T, Roth CL, Schernthaner GH, et al. Peptide YY and glucagon-like peptide-1 in morbidly obese patients before and after surgically induced weight loss. Obes Surg 2007;17:1571-1577
46. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000;21:697-738 (Pubitemid 32113289)
47. Wajchenberg BL, Giannella-Neto D, da Silva ME, Santos RF. Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm Metab Res 2002;34:616-621
48. Thorne A, Lonnqvist F, Apelman J, et al. A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord 2002;26:193-199 (Pubitemid 34151196)
49. Hamdy O, Porramatikul S, Al-Ozairi E. Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr Diabetes Rev 2006;2:367-373 (Pubitemid 44734225)
50. Azuma K, Heilbronn LK, Albu JB, et al. Adipose tissue distribution in relation to insulin resistance in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 2007;293:E435-42
51. Tousignant B, Faraj M, Conus F, et al. Body fat distribution modulates insulin sensitivity in post-menopausal overweight and obese women: a MONET study. Int J Obes 2008;In press. Doi:10.1038/ijo.2008.163
52. Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004;350:2549-2557 (Pubitemid 38758542)
53. Hocking SL, Chisholm DJ, James DE. Studies of regional adipose transplantation reveal a unique and beneficial interaction between subcutaneous adipose tissue and the intra-abdominal compartment. Diabetologia 2008;51:900-902
54. Tran TT, Yamamoto Y, Gesta S, Kahn CR. Beneficial effects of subcutaneous fat transplantation on metabolism. Cell Metab 2008;7:410-420 (Pubitemid 351598027)
55. Konrad D, Rudich A, Schoenle EJ. Improved glucose tolerance in mice receiving intraperitoneal transplantation of normal fat tissue. Diabetologia 2007;50:833-839 (Pubitemid 46355832)
56. Montague CT, Prins JB, Sanders L, et al. Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes 1998;47:1384-1391 (Pubitemid 28396940)
57. Rodríguez A, Catalán V, Gómez-Ambrosi J, Frühbeck G. Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome? Curr Pharm Des 2007;13:2169-2175
58. Zierath JR, Livingston JN, Thorne A, et al. Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway. Diabetologia 1998;41:1343-1354 (Pubitemid 28488763)
59. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998;83:847-850 (Pubitemid 28496456)
60. Bruun JM, Lihn AS, Madan AK, et al. Higher production of IL-8 in visceral vs. subcutaneous adipose tissue. Implication of nonadipose cells in adipose tissue. Am J Physiol Endocrinol Metab 2004;286:E8-13 (Pubitemid 38036603)
61. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-867 (Pubitemid 46024993)
62. Lihn AS, Bruun JM, He G, et al. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol 2004;219:9-15 (Pubitemid 38638516)
63. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000;11:327-332 (Pubitemid 30729003)
64. Frühbeck G, Gómez-Ambrosi J, Muruzabal FJ, Burrell MA. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 2001;280:E827-47 • An insightful review of the endocrine and metabolic signalling of adipocytes on energy homeostasis. (Pubitemid 32553225)
65. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-2556 (Pubitemid 38766330)
66. Gómez-Ambrosi J, Catalán V, Diez-Caballero A, et al. Gene expression profile of omental adipose tissue in human obesity. Faseb J 2004;18:215-217
67. Frühbeck G. Overview of adipose tissue and its role in obesity and metabolic disorders. Methods Mol Biol 2008;456:1-22
68. Catalán V, Rodríguez A, Becerril S, et al. Adipopharmacology of inflammation and insulin resistance. Biomedical Reviews 2006;17:43-51
69. Fain JN, Madan AK, Hiler ML, et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004;145:2273-2282 (Pubitemid 38535056)
70. Trayhurn P. Adipocyte biology. Obes Rev 2007;8:41-44 (Pubitemid 46272580)
71. Trayhurn P, Bing C, Wood IS. Adipose tissue and adipokines-energy regulation from the human perspective. J Nutr 2006;136:1935S-9S (Pubitemid 43973602)
72. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-432 •• A key paper dealing with the discovery and characterization of leptin. (Pubitemid 24365442)
73. Frühbeck G, Catalán V, Gómez-Ambrosi J, Rodríguez A. Aquaporin-7 and glycerol permeability as novel obesity drug-target pathways. Trends Pharmacol Sci 2006;27:345-347 (Pubitemid 43963182)
74. Gómez-Ambrosi J, Salvador J, Rotellar F, et al. Increased serum amyloid A concentrations in morbid obesity decrease after gastric bypass. Obes Surg 2006;16:262-269
75. Gómez-Ambrosi J, Catalán V, Ramírez B, et al. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab 2007;92:3719-3727 • First observation that plasma OPN and mRNA expression of OPN in omental adipose tissue are increased in overweight and obese patients. Description also of the effects of obesity-associated diabetes and weight loss. (Pubitemid 47435361)
76. Gualillo O, Gonzalez-Juanatey JR, Lago F. The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med 2007;17:275-283 (Pubitemid 350087698)
77. Lago F, Dieguez C, Gomez-Reino J, Gualillo O. Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 2007;3:716-724 (Pubitemid 350187017)
78. Catalán V, Gómez-Ambrosi J, Rodríguez A, et al. Expression of caveolin-1 in human adipose tissue is upregulated in obesity and obesity-associated type 2 diabetes mellitus and related to inflammation. Clin Endocrinol 2008;68:213-219
79. Furuhashi M, Fucho R, Gorgun CZ, et al. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest 2008;118:2640-2650 (Pubitemid 351949791)
80. Matsuzawa Y. Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006;3:35-42 (Pubitemid 43078211)
81. Frühbeck G. The Sir David Cuthbertson Medal Lecture. Hunting for new pieces to the complex puzzle of obesity. Proc Nutr Soc 2006;65:329-347
82. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-1830 (Pubitemid 38063705)
83. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-783 • An extensive and interesting review about the involvement of adipocytokines in the inflammation process of the adipose tissue and its link with the immune response. (Pubitemid 44453463)
84. Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 2008;14:222-231
85. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 1993;259:87-91 • First description of TNF-α as an adipocytokine and its association with insulin resistance.
86. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-1808 (Pubitemid 38063703)
87. Cancello R, Henegar C, Viguerie N, et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005;54:2277-2286 (Pubitemid 41134253)
88. Curat CA, Wegner V, Sengenes C, et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006;49:744-747 (Pubitemid 43357549)
89. Zeyda M, Stulnig TM. Adipose tissue macrophages. Immunol Lett 2007;112:61-67 (Pubitemid 47379852)
90. Wang P, Mariman E, Renes J, Keijer J. The secretory function of adipocytes in the physiology of white adipose tissue. J Cell Physiol 2008;216:3-13 (Pubitemid 351813090)
91. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-3670
92. Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-α. Cytokine Growth Factor Rev 2003;14:447-455 (Pubitemid 37099456)
93. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995;95:2409-2415
94. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992;130:43-52
95. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factorα inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994;91:4854-4858 (Pubitemid 24177748)
96. Klein J, Perwitz N, Kraus D, Fasshauer M. Adipose tissue as source and target for novel therapies. Trends Endocrinol Metab 2006;17:26-32 • A detailed and well-thought review focused on adipocyte-based therapies and future pharmacological options. (Pubitemid 43031381)
97. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006;189:47-60 (Pubitemid 44441296)
98. Frühbeck G. Intracellular signalling pathways activated by leptin. Biochem J 2006;393:7-20 (Pubitemid 43049298)
99. Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 2008;70:537-556 (Pubitemid 351738191)
100. Shimizu H, Oh IS, Okada S, Mori M. Leptin resistance and obesity. Endocr J 2007;54:17-26 (Pubitemid 46481666)
101. Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269:540-543
102. Shimomura I, Hammer RE, Ikemoto S, et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999;401:73-76 (Pubitemid 29418444)
103. Frühbeck G, Salvador J. Relation between leptin and the regulation of glucose metabolism. Diabetologia 2000;43:3-12 (Pubitemid 30129297)
104. Salvador J, Gómez-Ambrosi J, Frühbeck G. Perspectives in the therapeutic use of leptin. Expert Opin Pharmacother 2001;2:1615-1622 (Pubitemid 33019730)
105. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002;346:570-578 (Pubitemid 34438818)
106. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002;415:339-343 (Pubitemid 34087557)
107. Kamohara S, Burcelin R, Halaas JL, et al. Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 1997;389:374-377 (Pubitemid 27415217)
108. Covey SD, Wideman RD, McDonald C, et al. The pancreatic beta cell is a key site for mediating the effects of leptin on glucose homeostasis. Cell Metab 2006;4:291-302 (Pubitemid 44430918)
109. Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746-26749
110. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996;271:10697-10703 (Pubitemid 26145805)
111. Maeda K, Okubo K, Shimomura I, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996;221:286-9 • References 109-111 report the cloning and identification of adiponectin in mice and humans. (Pubitemid 26136463)
112. Nakano Y, Tobe T, Choi-Miura NH, et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 1996;120:803-812 (Pubitemid 26385421)
113. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-946 (Pubitemid 32756432)
114. Berg AH, Combs TP, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947-953 (Pubitemid 32756433)
115. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001;98:2005-2010 • First description of adiponectin directly influencing energy metabolism and body weight. (Pubitemid 32165613)
116. Yamamoto Y, Hirose H, Saito I, et al. Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab 2004;89:87-90 (Pubitemid 38183864)
117. Spranger J, Kroke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003;361:226-228 (Pubitemid 36126226)
118. Duncan BB, Schmidt MI, Pankow JS, et al. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2004;53:2473-2478 (Pubitemid 39145606)
119. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006;116:1784-1792 (Pubitemid 44033298)
120. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-451 (Pubitemid 40686653)
121. Qi Y, Takahashi N, Hileman SM, et al. Adiponectin acts in the brain to decrease body weight. Nat Med 2004;10:524-529 (Pubitemid 38667912)
122. Kubota N, Yano W, Kubota T, et al. Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab 2007;6:55-68 (Pubitemid 47007437)
123. Quadro L, Blaner WS, Salchow DJ, et al. Impaired retinal function and vitamin A availability in mice lacking retinol-binding protein. Embo J 1999;18:4633-4644 (Pubitemid 29415518)
124. Makover A, Soprano DR, Wyatt ML, Goodman DS. Localization of retinol-binding protein messenger RNA in the rat kidney and in perinephric fat tissue. J Lipid Res 1989;30:171-180 (Pubitemid 19067222)
125. Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356-62 • This study identifies RBP-4 as an adipocyte-derived 'signal' that may contribute to the pathogenesis of type 2 diabetes.
126. Graham TE, Yang Q, Bluher M, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006;354:2552-2563 (Pubitemid 43882351)
127. Kloting N, Graham TE, Berndt J, et al. Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab 2007;6:79-87 (Pubitemid 46995778)
128. Janke J, Engeli S, Boschmann M, et al. Retinol-binding protein 4 in human obesity. Diabetes 2006;55:2805-2810 (Pubitemid 44923680)
129. Yao-Borengasser A, Varma V, Bodles AM, et al. Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J Clin Endocrinol Metab 2007;92:2590-2597 (Pubitemid 47037362)
130. Broch M, Vendrell J, Ricart W, et al. Circulating retinol-binding protein-4, insulin sensitivity, insulin secretion, and insulin disposition index in obese and nonobese subjects. Diabetes Care 2007;30:1802-1806 (Pubitemid 47036355)
131. Vitkova M, Klimcakova E, Kovacikova M, et al. Plasma levels and adipose tissue messenger ribonucleic acid expression of retinol-binding protein 4 are reduced during calorie restriction in obese subjects but are not related to diet-induced changes in insulin sensitivity. J Clin Endocrinol Metab 2007;92:2330-2335 (Pubitemid 46997142)
132. Gómez-Ambrosi J, Rodríguez A, Catalán V, et al. Serum retinol-binding protein 4 is not increased in obesity or obesity-associated type 2 diabetes mellitus, but is reduced after relevant reductions in body fat following gastric bypass. Clin Endocrinol 2008:69:208-215 (Pubitemid 352009009)
133. Graham TE, Wason CJ, Bluher M, Kahn BB. Shortcomings in methodology complicate measurements of serum retinol binding protein (RBP-4) in insulin-resistant human subjects. Diabetologia 2007;50:814-823 (Pubitemid 46355817)
134. Samal B, Sun Y, Stearns G, et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994;14:1431-1437 (Pubitemid 24984261)
135. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-430 • This study identifies visfatin as a new adipokine mainly expressed in visceral fat that mimics insulin activity by binding and activating the insulin receptor. (Pubitemid 40139988)
136. Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005;54:2911-2916 (Pubitemid 41401086)
137. Arner P. Visfatin-a true or false trail to type 2 diabetes mellitus. J Clin Endocrinol Metab 2006;91:28-30 (Pubitemid 43069112)
138. Revollo JR, Korner A, Mills KF, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007;6:363-75 • The authors suggest that visfatin does not exert insulin-mimetic effects in vitro or in vivo, contributing to the controversy about the true pathophysiological contribution of visfatin. (Pubitemid 350011996)
139. Kralisch S, Klein J, Lossner U, et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 2005;185:R1-8 (Pubitemid 40883404)
140. Kralisch S, Klein J, Lossner U, et al. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 2005;289:E586-90
141. Fukuhara A, Matsuda M, Nishizawa M, et al. Retraction. Science 2007;318:565
142. Korner A, Garten A, Bluher M, et al. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007;92:4783-4791 (Pubitemid 350223461)
143. Flo TH, Smith KD, Sato S, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004;432:917-921 (Pubitemid 40037155)
144. Devireddy LR, Gazin C, Zhu X, Green MR. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 2005;123:1293-1305 (Pubitemid 41821786)
145. Triebel S, Blaser J, Reinke H, Tschesche H. A 25 kDa α-2- microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett 1992;314:386-388 (Pubitemid 23005695)
146. Liu Q, Nilsen-Hamilton M. Identification of a new acute phase protein. J Biol Chem 1995;270:22565-22570
147. Wang Y, Lam KS, Kraegen EW, et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 2007;53:34-41 • Lipocalin-2 is described as an inflammatory marker closely related to obesity and its metabolic complications. (Pubitemid 46047761)
148. Yan QW, Yang Q, Mody N, et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes 2007;56:2533-2540 (Pubitemid 47523260)
149. Zhang J, Wu Y, Zhang Y, et al. The role of lipocalin 2 in the regulation of inflammation in adipocytes and macrophages. Mol Endocrinol 2008;22:1416-1426 (Pubitemid 351787001)
150. Devireddy LR, Teodoro JG, Richard FA, Green MR. Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science 2001;293:829-834 (Pubitemid 32743967)
151. Lin Y, Rajala MW, Berger JP, et al. Hyperglycemia-induced production of acute phase reactants in adipose tissue. J Biol Chem 2001;276:42077-42083 (Pubitemid 37371113)
152. Aigner F, Maier HT, Schwelberger HG, et al. Lipocalin-2 regulates the inflammatory response during ischemia and reperfusion of the transplanted heart. Am J Transplant 2007;7:779-788 (Pubitemid 46481201)
153. Schaffler A, Neumeier M, Herfarth H, et al. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 2005;1732:96-102 (Pubitemid 43267310)
154. Kralisch S, Klein J, Bluher M, et al. Therapeutic perspectives of adipocytokines. Expert Opin Pharmacother 2005;6:863-872 • An extensive and thoughtful review about the function, regulation and therapeutic potential of various adipocytokines. (Pubitemid 40946152)
155. Yang RZ, Lee MJ, Hu H, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006;290:E1253-61 (Pubitemid 43847911)
156. de Souza Batista CM, Yang RZ, Lee MJ, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007;56:1655-1661 (Pubitemid 46842600)
157. Tan BK, Adya R, Farhatullah S, et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008;57:801-808
158. Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003;198:977-985 (Pubitemid 37248614)
159. Meder W, Wendland M, Busmann A, et al. Characterization of human circulating TIG2 as a ligand for the orphan receptor ChemR23. FEBS Lett 2003;555:495-499 (Pubitemid 37532599)
160. Zabel BA, Allen SJ, Kulig P, et al. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem 2005;280:34661-34666 (Pubitemid 41504597)
161. Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007;148:4687-4694 (Pubitemid 47481514)
162. Goralski KB, McCarthy TC, Hanniman EA, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007;282:28175-28188 (Pubitemid 47529521)
163. Takahashi M, Takahashi Y, Takahashi K, et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett 2008;582:573-578
164. Moldes M, Lasnier F, Gauthereau X, et al. Tumor necrosis factor-α-induced adipose-related protein (TIARP), a cell-surface protein that is highly induced by tumor necrosis factor-α and adipose conversion. J Biol Chem 2001;276:33938-33946 (Pubitemid 37384619)
165. Ohgami RS, Campagna DR, McDonald A, Fleming MD. The Steap proteins are metalloreductases. Blood 2006;108:1388-1394 (Pubitemid 44232042)
166. Korkmaz CG, Korkmaz KS, Kurys P, et al. Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer. Oncogene 2005;24:4934-4945 (Pubitemid 41129097)
167. Wellen KE, Fucho R, Gregor MF, et al. Coordinated regulation of nutrient and inflammatory responses by STAMP2 is essential for metabolic homeostasis. Cell 2007;129:537-548 (Pubitemid 46660973)
168. Arner P, Stenson BM, Dungner E, et al. Expression of six transmembrane protein of prostate 2 in human adipose tissue associates with adiposity and insulin resistance. J Clin Endocrinol Metab 2008;93:2249-2254 (Pubitemid 351831543)
169. Waki H, Tontonoz P. STAMPing out Inflammation. Cell 2007;129:451-452 (Pubitemid 46660981)
170. Brown LF, Berse B, Van de Water L, et al. Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Biol Cell 1992;3:1169-1180 (Pubitemid 23088966)
171. Denhardt DT, Noda M, O'regan AW, et al. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001;107:1055-1061 (Pubitemid 32422899)
172. Sodek J, Batista Da Silva AP, Zohar R. Osteopontin and mucosal protection. J Dent Res 2006;85:404-415 (Pubitemid 43799256)
173. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000;287:860-864 (Pubitemid 30084330)
174. El-Tanani MK, Campbell FC, Kurisetty V, et al. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 2006;17:463-474 (Pubitemid 44793123)
175. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007;27:2302-2309 (Pubitemid 350203943)
176. Nomiyama T, Perez-Tilve D, Ogawa D, et al. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest 2007;117:2877-2888 (Pubitemid 47529618)
177. Kiefer FW, Zeyda M, Todoric J, et al. Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. Endocrinology 2008;149:1350-1357
178. Gómez-Ambrosi J, Rodríguez A, Catalán V, Frühbeck G. The bone-adipose axis in obesity and weight loss. Obes Surg 2008;18:1134-1143
179. Ohmori R, Momiyama Y, Taniguchi H, et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003;170:333-337 (Pubitemid 37377807)
180. Yamaguchi H, Igarashi M, Hirata A, et al. Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients. Endocr J 2004;51:499-504 (Pubitemid 39536359)
181. Riedl M, Vila G, Maier C, et al. Plasma osteopontin increases after bariatric surgery and correlates with markers of bone turnover but not with insulin resistance. J Clin Endocrinol Metab 2008;93:2307-2312 (Pubitemid 351831552)
182. Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005;102:10610-10615 (Pubitemid 41061602)
183. Seeger J, Ziegelmeier M, Bachmann A, et al. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab 2008;93:247-251
184. Kloting N, Berndt J, Kralisch S, et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006;339:430-436 (Pubitemid 41697566)
185. Youn BS, Kloting N, Kratzsch J, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008;57:372-377
186. Tan BK, Heutling D, Chen J, et al. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 2008;57:1501-1507
187. de Ferranti S, Mozaffarian D. The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem 2008;54:945-955 (Pubitemid 351793400)
188. Barthel A, Herzig S, Muller HW, et al. RNA interference-based strategies for metabolic syndrome treatment. Horm Metab Res 2005;37:59-62 (Pubitemid 40445123)